SCHEMBL2913115

SCHEMBL2913115

CC(=O)OCCOc1cc(C)c(-c2cccc(C=O)c2C)cc1OCCOC(C)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
PTGDR2 Q9Y5Y4 2/20 0.38
PDCD1 Q15116 3/20 0.37
CD274 Q9NZQ7 3/20 0.37
TDP1 Q9NUW8 2/20 0.35
THRB P10828 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
ERN1 O75460 2/20 0.34
TLR2 O60603 1/20 0.34
TLR1 Q15399 1/20 0.34
TLR6 Q9Y2C9 1/20 0.34
MAPT P10636 4/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13117607 0.91 SMN1; SMN2 (0.37) ALDH1A1SMN1; SMN2HPGDHTTPTGDR2
SCHEMBL13117620 0.88 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2HPGDHTTPTGDR2
SCHEMBL2909825 0.85 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2HPGDHTTPTGDR2
SCHEMBL2909515 0.85 PDE3B (0.39) SMN1; SMN2PDCD1CD274TDP1NPC1
SCHEMBL13117618 0.83 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2HPGDHTTPTGDR2
SCHEMBL2913113 0.83 TSHR (0.48) ALDH1A1SMN1; SMN2HPGDHTTPTGDR2
SCHEMBL10203729 0.81 FFAR1 (0.35) ALDH1A1SMN1; SMN2HPGDHTTPDCD1
SCHEMBL13117473 0.80 MAPT (0.42) ALDH1A1SMN1; SMN2HPGDHTTPDCD1
SCHEMBL13117609 0.80 PDCD1 (0.35) ALDH1A1SMN1; SMN2HPGDHTTPTGDR2
SCHEMBL13117595 0.79 HTT (0.35) ALDH1A1SMN1; SMN2HPGDHTTPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 US disclosed
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 US disclosed
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 US disclosed
EP-2216330-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2010-08-11 EP disclosed
EP-2216330-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2010-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND GPR119, GLP1R, GPR4 ALDH1A1 2370/4885SMN1; SMN2 3468/4885HPGD 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.